País: Armênia
Língua: inglês
Origem: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
etoricoxib
Salutas Pharma GmbH
M01AH05
etoricoxib
90mg
tablets film-coated
(28/2x14/) in blister
Prescription
Registered
2018-08-31
m13 - statement-spc_am_en - 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT KOSTAROX® film-coated tablets 60 mg, 90 mg, 120 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION The active substance is etoricoxib. Each film-coated tablet contains 60 mg, 90 mg or 120 mg of etoricoxib. For the list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets _Description_: 60 mg: dark green, round, biconvex film-coated tablets. 90 mg: white, round, biconvex film-coated tablets. 120 mg: pale green, round, biconvex film-coated tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Kostarox is indicated in adults and adolescents 16 years of age and older for: - the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis, - the short-term treatment of moderate pain associated with dental surgery. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient’s overall risks (see sections 4.3 and 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient’s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1). _Osteoarthritis_ The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. _Rheumatoid arthritis_ The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a Leia o documento completo